Axsome Competitors
| AXSM Stock | USD 186.21 1.91 1.04% |
Axsome Therapeutics vs Jazz Pharmaceuticals Correlation
Modest diversification
The correlation between Axsome Therapeutics and JAZZ is 0.28 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Axsome Therapeutics and JAZZ in the same portfolio, assuming nothing else is changed.
Moving together with Axsome Stock
| 0.82 | JNJ | Johnson Johnson | PairCorr |
| 0.62 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.94 | LPCN | Lipocine | PairCorr |
Moving against Axsome Stock
| 0.92 | HPQ | HP Inc | PairCorr |
| 0.75 | MSFT | Microsoft | PairCorr |
| 0.58 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.47 | IBM | International Business | PairCorr |
| 0.38 | VLCN | Volcon Inc Symbol Change | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Axsome Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Axsome Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Axsome and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Axsome Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Axsome Stock performing well and Axsome Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Axsome Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | 2.14 | 0.13 | 0.02 | 1.28 | 2.54 | 3.45 | 17.72 | |||
| MTSR | 4.01 | 1.62 | 0.45 | (4.60) | 2.40 | 14.25 | 75.60 | |||
| ABVX | 3.20 | 0.33 | 0.07 | 2.28 | 3.39 | 6.94 | 29.38 | |||
| CYTK | 2.19 | 0.09 | 0.04 | 0.19 | 2.25 | 4.25 | 12.08 | |||
| RYTM | 2.38 | (0.05) | (0.02) | 0.04 | 2.83 | 4.76 | 18.69 | |||
| ARWR | 3.36 | 0.61 | 0.19 | 0.44 | 2.87 | 10.85 | 32.02 | |||
| CRSP | 2.67 | (0.36) | 0.00 | (0.10) | 0.00 | 5.51 | 19.81 | |||
| PCVX | 2.44 | 0.51 | 0.17 | (10.59) | 2.19 | 6.71 | 15.14 | |||
| JAZZ | 1.67 | 0.42 | 0.14 | (0.60) | 1.62 | 3.66 | 25.96 |
Cross Equities Net Income Analysis
Compare Axsome Therapeutics and related stocks such as Nuvalent, Metsera Common Stock, and Abivax SA American Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (260.8 M) | (234.7 M) | (222.9 M) |
| ABVX | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.1 M) | (16 M) | (14.3 M) | (11.2 M) | (15.8 M) | (30.6 M) | (37.6 M) | (42.5 M) | (60.7 M) | (147.7 M) | (176.2 M) | (158.6 M) | (150.7 M) |
| CYTK | (13.1 M) | (47.9 M) | (41.7 M) | (33.7 M) | (14.6 M) | (37.5 M) | 16.5 M | (127.8 M) | (106.3 M) | (121.7 M) | (127.3 M) | (215.3 M) | (389 M) | (526.2 M) | (589.5 M) | (530.6 M) | (504 M) |
| RYTM | (18.1 M) | (18.1 M) | (18.1 M) | (21.4 M) | (6.5 M) | (11.1 M) | (25.9 M) | (33.7 M) | (74.1 M) | (134.6 M) | (130.7 M) | (68 M) | (181.1 M) | (184.7 M) | (260.6 M) | (234.5 M) | (222.8 M) |
| ARWR | (854.5 K) | (21.1 M) | (31.1 M) | (58.6 M) | (91.9 M) | (81.7 M) | (34.4 M) | (54.5 M) | 68 M | (84.6 M) | (140.8 M) | (176.5 M) | (205.3 M) | (599.5 M) | (1.6 M) | (1.5 M) | (1.5 M) |
| CRSP | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (25.8 M) | (23.2 M) | (68.4 M) | (165 M) | 66.9 M | (348.9 M) | 377.7 M | (650.2 M) | (153.6 M) | (366.3 M) | (329.6 M) | (313.1 M) |
| PCVX | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (29.5 M) | (50.3 M) | (89.2 M) | (100.1 M) | (223.5 M) | (402.3 M) | (463.9 M) | (417.5 M) | (396.7 M) |
| JAZZ | (24.8 M) | 125 M | 288.6 M | 216.3 M | 58.4 M | 329.5 M | 396.8 M | 487.8 M | 447.1 M | 523.4 M | 238.6 M | (329 M) | (224.1 M) | 414.8 M | 560.1 M | 644.1 M | 676.3 M |
Axsome Therapeutics and related stocks such as Nuvalent, Metsera Common Stock, and Abivax SA American Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Axsome Therapeutics financial statement analysis. It represents the amount of money remaining after all of Axsome Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Axsome Therapeutics Competitive Analysis
The better you understand Axsome Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Axsome Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Axsome Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Axsome Therapeutics Competition Performance Charts
Five steps to successful analysis of Axsome Therapeutics Competition
Axsome Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Axsome Therapeutics in relation to its competition. Axsome Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Axsome Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Axsome Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Axsome Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Axsome Therapeutics position
In addition to having Axsome Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cars Thematic Idea Now
Cars
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Axsome Therapeutics Correlation with its peers. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.66) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.